Table 3.

Differential effects of the T2 biologics mepolizumab, benralizumab, dupilumab, and omalizumab in SA patients with CRSwNP. For the pulmonary parameters, no significant results were detectable. The nasal parameters in the dupilumab group were scored significantly better than the other T2 biologics. Statistics: Pairwise comparisons were performed if the Kruskal-Wallis test was significant (p < 0.05). A Bonferroni correction was applied

FEV1: Forced Expiratory Volume in 1 Second; ACT: Asthma Control Test; VAS: Visual Analogue Scale; RSOM: Rhinosinusitis Outcome Measurement; SA: Severe Asthma, CRSwNP: Chronic Rhinosinusitis with Nasal Polyps; M = mepolizumab; B = benralizumab; D = dupilumab; O = omalizumab; sig = significance; green: better effect for first drug vs second drug; orange: worse effect for first drug vs second drug; n.t. = not tested; n.s. = not significant; vs = versus; ∗ = p < 0.05; ∗∗ = p < 0.01; ∗∗∗ = p < 0.001.